十年儿童高级别胶质瘤再放疗经验对一线治疗的启示
该研究回顾性分析了2010至2021年间21例复发儿童高级别胶质瘤患者的再放疗情况,所有患者初诊时均接受手术、放疗和化疗。再放疗后中位进展时间为3.7个月,中位生存时间为6.9个月;首次放疗与再放疗间隔较长者及再放疗后非进展者生存改善。作者认为鉴于复发时观察到的播散现象,结果可提示在随机试验中研究不同的一线放疗野。
要点
- 21例复发儿童高级别胶质瘤患者再放疗后中位进展时间3.7个月,中位生存时间6.9个月。
- 再放疗后生存改善与首次放疗至再放疗间隔较长(P=0.017)及再放疗后非进展(P<0.001)相关。
- 首次边缘复发与再放疗后播散可能存在关联(P=0.081)。
核心结论
- 这是儿童高级别胶质瘤再放疗的最大样本系列。
- 鉴于复发时观察到的播散现象,作者认为结果可提示在随机试验中研究不同的一线放疗野。
研究设计与样本
- 回顾性分析2010至2021年间21例复发高级别胶质瘤患者,年龄小于18岁。
- 所有患者初诊时均接受手术、放疗和化疗。
- 对20/21例患者依据WHO 2021标准进行病理/分子再评估分类。
- 进行了生存分析及与临床参数的关联分析。
主要发现
- 首次放疗后复发为局部12例(其中边缘7例)、播散4例、局部+播散5例。
- 再放疗获得8例疾病稳定、1例部分缓解、1例假性进展、1例混合反应、10例疾病进展;8例神经症状/体征改善。
- 12例接受局部再放疗,其中10/12例可评估者中6例再次局部复发(2例边缘)和4例局部+播散复发。
- 4例播散者接受全脑放疗1例、颅脊照射2例、脊柱再放疗1例,3/4例可评估者进一步出现播散和局部+播散复发。
- 5例局部+播散肿瘤接受颅脊照射3例、脊柱再放疗1例,进一步局部进展2例、播散1例、不可评估1例。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Recurrence incidence for paediatric/adolescent high-grade glioma (HGG) exceeds 80%. Reirradiation (reRT) palliates symptoms and delays further progression. Strategies for reRT are scarce: we retrospectively analysed our series to develop rational future approaches. METHODS: We re-evaluated MRI + RT plans of 21 relapsed HGG-patients, accrued 2010-2021, aged under 18 years. All underwent surgery and RT + chemotherapy at diagnosis. Pathologic/molecular re-evaluation allowed classification based on WHO 2021 criteria in 20/21 patients. Survival analyses and association with clinical parameters were performed. RESULTS: Relapse after 1st RT was local in 12 (7 marginal), 4 disseminated, 5 local + disseminated. Re-RT obtained 8 SD, 1 PR, 1PsPD, 1 mixed response, 10 PD; neurological signs/symptoms improved in 8. Local reRT was given to 12, followed again by 6 local (2 marginal) and 4 local + disseminated second relapses in 10/12 re-evaluated. The 4 with dissemination had 1 whole brain, 2 craniospinal irradiation (CSI), 1 spine reRT and further relapsed with dissemination and local + dissemination in 3/four assessed. Five local + disseminated tumours had 3 CSI, 1 spine reRT, further progressing locally (2), disseminated (1), n.a. (1). Three had a third RT; three were alive at 19.4, 29, 50.3 months after diagnosis. Median times to progression/survival after re-RT were 3.7 months (0.6-16.2 months)/6.9 months (0.6-17.9 months), improved for longer interval between 1st RT and re-RT (P = 0.017) and for non-PD after reRT (P < 0.001). First marginal relapse showed potential association with dissemination after re-RT (P = 0.081). CONCLUSIONS: This is the biggest series of re-RT in paediatric HGG. Considering the dissemination observed at relapse, our results could prompt the investigation of different first RT fields in a randomized trial.
引用
- Massimino M, Vennarini S, Barretta F, et al. How ten-years of reirradiation for paediatric high-grade glioma may shed light on first line treatment. J Neurooncol. 2022. PMID: 35809148. doi:10.1007/s11060-022-04079-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。